SlideShare uma empresa Scribd logo
1 de 24
(-)-Epicatechin Selectively Radiosensitizes Cancer Cells and
Stimulates Mitochondrial Activity in Cancer Cells by
Inhibiting MAPK Pathway
Hosam A. Elbaz, Ph.D.
March 12th, 2014
Department of Radiation Oncology,
Center for Molecular Medicine and Genetics,
Wayne State University
Detroit, MI 48201.
Overview
• Introduction
• What is (-)-Epicatechin?
• Experimental methods
• (-)-Epicatechin and Mitochondrial Respiration
• (-)-Epicatechin and Radiosensitization
• Potential Mechanisms
• Conclusion and Future Directions
Introduction
• Radiotherapy is ideal for most solid tumors.
• Radiation resistance and adverse effects are frequently encountered.
• Radiosensitizing agents would improve therapeutic outcome.
• Most cancer types exhibit 40-60% reduction in mitochondrial activity and
rely on aerobic glycolysis for energy (Warburg effect).
• Drugs that increase mitochondrial respiration would interfere with the
Warburg effect and could sensitize cancer cells to conventional therapy.
What is (-)-Epicatechin?
• A natural polyphenolic flavanol
– Flavonoid family
– Natural ingredient in cacao, green tea and dark chocolate
– Antioxidant properties
• Molecular Weight: 290.268097 Da
• IUPAC name: (2R,3R)-2-(3,4-dihydroxyphenyl)-3,4-dihydro-2H-chromene-3,5,7-triol
• It has a number of beneficial health effects.
(-)-Epicatechin stimulated mitochondrial respiration and ETC
protein expression
Hüttemann H et al. FASEB J. 2012; vol. 26 no. 4 1413-1422
Short term treatment of 40 µM (-)-Epicatechin enhances
cytochrome c oxidase activity
p < 0.05;
* and ** compared to
control
0
20
40
60
80
100
120
140
160
180
0 5 10 15 20 25 30 35
CcOSpecificActivity
[O2nmol/min/mgoftotalprotein]
Cytc [µM]
Control
5 min
20 min
**
*
General hypothesis
↑ COX activity
↑ Mitochondrial respiration in cancer cells
↓ The Warburg metabolism and
↑ ROS production in cancer cells
↑ Cellular stress
↑ Sensitivity to cell death
(-)-Epicatechin
Experimental methods
• Cytochrome c oxidase activity
• Cell lines:
• Panc-1
• MIA PaCa-2
• U87
• Normal human dermal
fibroblasts (NHDF)
• Clonogenic survival assay
• Enzymes for checkpoint and
OXPHOS complexes
• P-Chk2: phosphorylated
checkpoint kinase protein 2 at
Thr68
• p21.
• P-Erk2: phosphorylated
extracellular kinase 2
• OXPHOS complexes:
• Complex I: NDUFB6
subunit
• Complex II: 70kDa subunit
• Complex III: Core 1 subunit
• Complex IV: subunit 1
• Complex V: α subunit
(-)-Epicatechin increases mitochondrial activity in Panc-1
cells but not in normal human dermal fibroblast (NHDF) cells
COX activity for Panc-1 Cells
(-)-Epicatechin (M)
O2consumption
(nmol/min/mgprotein)
0 20 50 100 200
0
10
20
30
*
*
*
COX activity for NHDF Cells
(-)-Epicatechin (M)
O2consumption
(nmol/min/mgprotein)
0 100
0
5
10
15
A B
(-)-Epicatechin sensitizes cancer cell lines to irradiation
Panc-1
IR dose (Gy)
Survivalfraction
0 2 4 6 8
0.01
0.1
1
Control
(-)-Epicatechin (20 M)
U87
IR dose (Gy)
Survivalfraction
0 2 4 6 8
0.01
0.1
1 Control
(-)-Epicatechin (20 M)
MIA PaCa-2
IR dose (Gy)
Survivalfraction
0 2 4 6 8
0.01
0.1
1 Control
(-)-Epicatechin (20 M)
A B C
D E(-)-Epicatechin alone
(-)-Epicatechin (M)
Survivalfraction
0 25 50 100 200
0.0
0.2
0.4
0.6
0.8
*
*
(-)-Epicatechin + 6 Gy
(-)-Epicatechin (M)
Survivalfraction
0 25 50 100 200
0.00
0.02
0.04
0.06
0.08
*
*
*
(-)-Epicatechin does not sensitize NHDF cells to radiation.
NHDF Cells
IR dose (Gy)
Survivalfraction
0 2 4 6 8
0.01
0.1
1 Control
(-)-Epicatechin (20 M)
A B C
NHDF Survival with EC and 6Gy
(-)-Epicatechin (M)
Survivalfraction
0 100
0.000
0.001
0.002
0.003
*
NHDF Survival with EC alone
(-)-Epicatechin (M)
Survivalfraction
0 20
0.00
0.02
0.04
0.06
0.08
(-)-Epicatechin and irradiation modestly manipulate ETC
protein expression
RelativeexpressionC
om
1-N
D
U
FP6C
om
2-70kD
aC
om
3-core
1
C
O
X-1
1
C
om
5-
0.0
0.5
1.0
1.5
2.0
0 M / 0 Gy
20 M / 0 Gy
100 M / 0 Gy
200 M / 0 Gy
Relativeexpression
C
om
1-N
D
U
FP6C
om
2-70kD
aC
om
3-core
1
C
O
X-1
1
C
om
5-
0.0
0.5
1.0
1.5
2.0
0 M / 6 Gy
20 M / 6 Gy
100 M / 6 Gy
200 M / 6 Gy**
B C
Hypothesis: Activating cytochrome c oxidase increases
mitochondrial membrane potential m and free radical
production.
O2
•–generation
[nmol/mg/min]
H2O2generation
[nmol/mg/min]
[Reviewed in Liu, S. (1999) J Bioenerg Biomembr 31:367-76]
[Reviewed in Bin-Bing S. Zhou & Jiri Bartek.
(2004) Nature Reviews Cancer 4, 216-225]
(-)-Epicatechin and irradiation stimulate Chk2
phosphorylation (Thr68) and p21 expression in Panc-1 Cells.
p21 in 6 Gy Exposed Cells
(-)-Epicatechin (M)Relativeexpression
0 20
0.0
0.5
1.0
1.5
2.0
*
A B
0 Gy 6 Gy
- + - +
IR
(-)-Epicatechin 20 µM
p21
GAPDH
0 Gy 6 Gy
- + - +
IR
(-)-Epicatechin 20 µM
P-Chk2
Chk2
GAPDH
P-Chk2 in 6 Gy Exposed Cells
(-)-Epicatechin (M)
Relativeexpression
0 20
0.0
0.5
1.0
1.5
2.0
*
(-)-Epicatechin and irradiation do not stimulate Chk2
phosphorylation or p21 expression in NHDF cells
A B
(-)-Epicatechin stimulates caspase 3 cleavage in Panc-1 cells.
Pro-caspase 3
Cleaved caspase 3
β-actin
- + - +(-)-Epicatechin
IR 0 Gy 6 Gy
EGFR signalling inhibits mitochondrial function.
Demory M L et al. J. Biol. Chem. 2009;284:36592-36604
Modified from Hüttemann H et al. Adv. Exp.
Med. Biol. 2012;748:237-64
Receptor tyrosine kinase signaling ↑
EGFR translocation to
the mitochondria
COX activity ↓
Warburg metabolism ↑
∞
Cell proliferation
MAPK members
interact with COX
(-)-Epicatechin
(-)-Epicatechin and radiation inhibit Erk phosphorylation in
Panc-1 cells
A
P-Erk1/2
Erk1/2
(-)-Epicatechin (µM)
0 20 50 100 200
GAPDH
B
6Gy +
(-)-Epicatechin (µM)
0 20 50
P- Erk1/2
Erk1/2
GAPDH
Erk2 phosphorylation in Panc-1 cells
(-)-Epicatechin (M)
Relativeexpression
0 20 50 100 200
0.00
0.25
0.50
0.75
1.00
1.25
*
*
*
P-Erkin6GyExposedPanc-1Cells
(-)-Epicatechin(M)
Relativeexpression
0 20 50
0.0
0.2
0.4
0.6
0.8
1.0 *
EGF reverses (-)-epicatechin’s stimulation of mitochondrial
respiration in Panc-1 cells
O2consumption
(nmol/min/mgprotein)
Control EC EGF EC+EGF
0
5
10
15
20
25
* *
EGF reverses (-)-epicatechin’s inhibition of Panc-1 clonogenic
survival
Survivalfraction
Control EC EGF EC+EGF
0.0
0.5
1.0
1.5
2.0
2.5
*
*
*
Discussion and Conclusion
• (-)-Epicatechin
– Increases COX activity and
potentially reverses Warburg
effect.
– “selectively” sensitizes cancer
cells to irradiation.
• (-)-Epicatechin and radiation
– increased P-Chk2 and p21 levels
in Panc-1 cells
– No effect in NHDF cells.
• (-)-Epicatechin with or without
radiation.
– reduced Erk phosphorylation
• (-)-Epicatechin reduced EGF’s effect
mitochondrial activity and Panc-1
clonogenesis.
(-)-Epicatechin
↑ COX activity
↑ Mitochondrial respiration in cancer cells
↓ Warburg metabolism
↓Cell proliferation
↑ Cellular stress
↓ MAPK signaling
↑ Sensitivity to cell death
Future Directions
• How does (-)-epicatechin regulate mitochondrial respiration via MAPK
signaling in cancer cells?
• Is (-)-epicatechin’s radiosensitization mediated by reduced MAPK
signaling?
• How does (-)-epicatechin’s effect on MAPK signaling cause
radiosensitization in cancer cells?
• Can (-)-epicatechin be used as a radiosensitizer in vivo?
• Animal model examination
• Efficacy vs. safety
• Can (-)-epicatechin sensitize cancer cells to chemotherapy?
Acknowledgements
• Principle investigators
– Steven Zielske
– Maik Hüttemann
• Angelika Burger Shared
Postdoctoral Award, Karmanos
Cancer Institute
• Department of Radiation
Oncology
• Center for Molecular Medicine
and Genetics
• WSU Office for Vice President for
Research
• Zielske lab
– Current members
• Morgan Laney
– Former members
• Ethan Brock
• Aisha Fasih
• Deborah Antwih
• Kristina Gabbarah
• Hüttemann lab
– Icksoo Lee
– Jenney Liu
– Joseph Shay
– Gargi Mahapatra
Questions?

Mais conteúdo relacionado

Mais procurados

Predictive Models for Mechanism of Action Classification from Phenotypic Assa...
Predictive Models for Mechanism of Action Classification from Phenotypic Assa...Predictive Models for Mechanism of Action Classification from Phenotypic Assa...
Predictive Models for Mechanism of Action Classification from Phenotypic Assa...Ellen Berg
 
Mechanism of protection by daily...
Mechanism of protection by daily...Mechanism of protection by daily...
Mechanism of protection by daily...mothersafe
 
Personalized & Translational Medicine - KineMed, Inc. - Marc Hellerstein, MD,...
Personalized & Translational Medicine - KineMed, Inc. - Marc Hellerstein, MD,...Personalized & Translational Medicine - KineMed, Inc. - Marc Hellerstein, MD,...
Personalized & Translational Medicine - KineMed, Inc. - Marc Hellerstein, MD,...KineMed, Inc.
 
Buck anti aggregation opportunity feb2013 eng
Buck anti aggregation opportunity feb2013 engBuck anti aggregation opportunity feb2013 eng
Buck anti aggregation opportunity feb2013 engEgor Sulkin
 
Antibody drug conjugates current status and future perspectives
Antibody drug conjugates  current status and future perspectivesAntibody drug conjugates  current status and future perspectives
Antibody drug conjugates current status and future perspectivesPranav Sopory
 
Impacts of genomics, proteomics, and metabolomics ppt
Impacts of genomics, proteomics, and metabolomics pptImpacts of genomics, proteomics, and metabolomics ppt
Impacts of genomics, proteomics, and metabolomics pptGloria Okenze
 
Biochemical and bioinformatic investigations of potential drug targets in Pla...
Biochemical and bioinformatic investigations of potential drug targets in Pla...Biochemical and bioinformatic investigations of potential drug targets in Pla...
Biochemical and bioinformatic investigations of potential drug targets in Pla...Greg Crowther
 
Systems Pharmacology as a tool for future therapy development: a feasibility ...
Systems Pharmacology as a tool for future therapy development: a feasibility ...Systems Pharmacology as a tool for future therapy development: a feasibility ...
Systems Pharmacology as a tool for future therapy development: a feasibility ...Guide to PHARMACOLOGY
 
Mass Spectrometry-Based Proteomics Quantification: iTRAQ
Mass Spectrometry-Based Proteomics Quantification: iTRAQ Mass Spectrometry-Based Proteomics Quantification: iTRAQ
Mass Spectrometry-Based Proteomics Quantification: iTRAQ Creative Proteomics
 
Defining Chemical Target and Pathway Toxicity Mechanisms with Primary Human C...
Defining Chemical Target and Pathway Toxicity Mechanisms with Primary Human C...Defining Chemical Target and Pathway Toxicity Mechanisms with Primary Human C...
Defining Chemical Target and Pathway Toxicity Mechanisms with Primary Human C...BioMAP® Systems
 
Drug-to-protein mappings in the Guide to PHARMACOLOGY: Utility as a target va...
Drug-to-protein mappings in the Guide to PHARMACOLOGY: Utility as a target va...Drug-to-protein mappings in the Guide to PHARMACOLOGY: Utility as a target va...
Drug-to-protein mappings in the Guide to PHARMACOLOGY: Utility as a target va...Guide to PHARMACOLOGY
 
Premier on Medicinal Fungus as effective Adjuvant & Complementary Agents for ...
Premier on Medicinal Fungus as effective Adjuvant & Complementary Agents for ...Premier on Medicinal Fungus as effective Adjuvant & Complementary Agents for ...
Premier on Medicinal Fungus as effective Adjuvant & Complementary Agents for ...Chee-Cheow Lee
 
Effect of Antioxidant status on liver following Atrazine exposure and its pro...
Effect of Antioxidant status on liver following Atrazine exposure and its pro...Effect of Antioxidant status on liver following Atrazine exposure and its pro...
Effect of Antioxidant status on liver following Atrazine exposure and its pro...IOSR Journals
 
Tumour inhibitors from plants final
Tumour inhibitors from plants finalTumour inhibitors from plants final
Tumour inhibitors from plants finalSiddhesh Bhende
 
Biologcals basics and their uses in rheumatological disorders ppt
Biologcals  basics and their uses in rheumatological disorders pptBiologcals  basics and their uses in rheumatological disorders ppt
Biologcals basics and their uses in rheumatological disorders pptNilesh Jadhav
 
Polymers and Hydrogels for Stabilization and Delivery of Animal Feed Enzymes ...
Polymers and Hydrogels for Stabilization and Delivery of Animal Feed Enzymes ...Polymers and Hydrogels for Stabilization and Delivery of Animal Feed Enzymes ...
Polymers and Hydrogels for Stabilization and Delivery of Animal Feed Enzymes ...BASF
 
Multi Target Bioactivity Models in Pipeline Pilot
Multi Target Bioactivity Models in Pipeline PilotMulti Target Bioactivity Models in Pipeline Pilot
Multi Target Bioactivity Models in Pipeline PilotGerard van Westen
 

Mais procurados (20)

Foodomics
FoodomicsFoodomics
Foodomics
 
Predictive Models for Mechanism of Action Classification from Phenotypic Assa...
Predictive Models for Mechanism of Action Classification from Phenotypic Assa...Predictive Models for Mechanism of Action Classification from Phenotypic Assa...
Predictive Models for Mechanism of Action Classification from Phenotypic Assa...
 
Mechanism of protection by daily...
Mechanism of protection by daily...Mechanism of protection by daily...
Mechanism of protection by daily...
 
Personalized & Translational Medicine - KineMed, Inc. - Marc Hellerstein, MD,...
Personalized & Translational Medicine - KineMed, Inc. - Marc Hellerstein, MD,...Personalized & Translational Medicine - KineMed, Inc. - Marc Hellerstein, MD,...
Personalized & Translational Medicine - KineMed, Inc. - Marc Hellerstein, MD,...
 
Buck anti aggregation opportunity feb2013 eng
Buck anti aggregation opportunity feb2013 engBuck anti aggregation opportunity feb2013 eng
Buck anti aggregation opportunity feb2013 eng
 
Antibody drug conjugates current status and future perspectives
Antibody drug conjugates  current status and future perspectivesAntibody drug conjugates  current status and future perspectives
Antibody drug conjugates current status and future perspectives
 
Impacts of genomics, proteomics, and metabolomics ppt
Impacts of genomics, proteomics, and metabolomics pptImpacts of genomics, proteomics, and metabolomics ppt
Impacts of genomics, proteomics, and metabolomics ppt
 
Biochemical and bioinformatic investigations of potential drug targets in Pla...
Biochemical and bioinformatic investigations of potential drug targets in Pla...Biochemical and bioinformatic investigations of potential drug targets in Pla...
Biochemical and bioinformatic investigations of potential drug targets in Pla...
 
Systems Pharmacology as a tool for future therapy development: a feasibility ...
Systems Pharmacology as a tool for future therapy development: a feasibility ...Systems Pharmacology as a tool for future therapy development: a feasibility ...
Systems Pharmacology as a tool for future therapy development: a feasibility ...
 
Mass Spectrometry-Based Proteomics Quantification: iTRAQ
Mass Spectrometry-Based Proteomics Quantification: iTRAQ Mass Spectrometry-Based Proteomics Quantification: iTRAQ
Mass Spectrometry-Based Proteomics Quantification: iTRAQ
 
Defining Chemical Target and Pathway Toxicity Mechanisms with Primary Human C...
Defining Chemical Target and Pathway Toxicity Mechanisms with Primary Human C...Defining Chemical Target and Pathway Toxicity Mechanisms with Primary Human C...
Defining Chemical Target and Pathway Toxicity Mechanisms with Primary Human C...
 
Drug-to-protein mappings in the Guide to PHARMACOLOGY: Utility as a target va...
Drug-to-protein mappings in the Guide to PHARMACOLOGY: Utility as a target va...Drug-to-protein mappings in the Guide to PHARMACOLOGY: Utility as a target va...
Drug-to-protein mappings in the Guide to PHARMACOLOGY: Utility as a target va...
 
Premier on Medicinal Fungus as effective Adjuvant & Complementary Agents for ...
Premier on Medicinal Fungus as effective Adjuvant & Complementary Agents for ...Premier on Medicinal Fungus as effective Adjuvant & Complementary Agents for ...
Premier on Medicinal Fungus as effective Adjuvant & Complementary Agents for ...
 
Effect of Antioxidant status on liver following Atrazine exposure and its pro...
Effect of Antioxidant status on liver following Atrazine exposure and its pro...Effect of Antioxidant status on liver following Atrazine exposure and its pro...
Effect of Antioxidant status on liver following Atrazine exposure and its pro...
 
Tumour inhibitors from plants final
Tumour inhibitors from plants finalTumour inhibitors from plants final
Tumour inhibitors from plants final
 
Biologcals basics and their uses in rheumatological disorders ppt
Biologcals  basics and their uses in rheumatological disorders pptBiologcals  basics and their uses in rheumatological disorders ppt
Biologcals basics and their uses in rheumatological disorders ppt
 
Polymers and Hydrogels for Stabilization and Delivery of Animal Feed Enzymes ...
Polymers and Hydrogels for Stabilization and Delivery of Animal Feed Enzymes ...Polymers and Hydrogels for Stabilization and Delivery of Animal Feed Enzymes ...
Polymers and Hydrogels for Stabilization and Delivery of Animal Feed Enzymes ...
 
B0343014018
B0343014018B0343014018
B0343014018
 
Multi Target Bioactivity Models in Pipeline Pilot
Multi Target Bioactivity Models in Pipeline PilotMulti Target Bioactivity Models in Pipeline Pilot
Multi Target Bioactivity Models in Pipeline Pilot
 
د. هدير ماهر
د. هدير ماهرد. هدير ماهر
د. هدير ماهر
 

Destaque

Este blog fue creado por alumnos de cbtis 231 del cuarto semestre grupo
Este blog fue creado por alumnos de cbtis 231 del cuarto semestre grupoEste blog fue creado por alumnos de cbtis 231 del cuarto semestre grupo
Este blog fue creado por alumnos de cbtis 231 del cuarto semestre grupoMaji Ortiz
 
Symposiium 14 Registration Book
Symposiium 14 Registration BookSymposiium 14 Registration Book
Symposiium 14 Registration BookKaren Baker, LICSW
 
Reading british & american culture syllabus 2011
Reading british & american culture syllabus 2011Reading british & american culture syllabus 2011
Reading british & american culture syllabus 2011Amy Hayashi
 
Social Web Today power pointx
Social Web Today power pointxSocial Web Today power pointx
Social Web Today power pointxPastor Randy Lee
 
Centro de bachillerato tecnológico industrial y de servicio
Centro de bachillerato tecnológico industrial y de servicioCentro de bachillerato tecnológico industrial y de servicio
Centro de bachillerato tecnológico industrial y de servicioMaji Ortiz
 
MiRNA presentation
MiRNA presentationMiRNA presentation
MiRNA presentationjthouse1928
 

Destaque (13)

Thesis
ThesisThesis
Thesis
 
Este blog fue creado por alumnos de cbtis 231 del cuarto semestre grupo
Este blog fue creado por alumnos de cbtis 231 del cuarto semestre grupoEste blog fue creado por alumnos de cbtis 231 del cuarto semestre grupo
Este blog fue creado por alumnos de cbtis 231 del cuarto semestre grupo
 
Cronograma
CronogramaCronograma
Cronograma
 
Blogg
BloggBlogg
Blogg
 
Symposiium 14 Registration Book
Symposiium 14 Registration BookSymposiium 14 Registration Book
Symposiium 14 Registration Book
 
Reading british & american culture syllabus 2011
Reading british & american culture syllabus 2011Reading british & american culture syllabus 2011
Reading british & american culture syllabus 2011
 
Social Web Today power pointx
Social Web Today power pointxSocial Web Today power pointx
Social Web Today power pointx
 
33
3333
33
 
Diagrama de medios
Diagrama de mediosDiagrama de medios
Diagrama de medios
 
Taller biblios
Taller bibliosTaller biblios
Taller biblios
 
Centro de bachillerato tecnológico industrial y de servicio
Centro de bachillerato tecnológico industrial y de servicioCentro de bachillerato tecnológico industrial y de servicio
Centro de bachillerato tecnológico industrial y de servicio
 
Antileprotic drugs
Antileprotic drugsAntileprotic drugs
Antileprotic drugs
 
MiRNA presentation
MiRNA presentationMiRNA presentation
MiRNA presentation
 

Semelhante a UMich meeting seminar on 03-12-2014 v1.pptx [Autosaved]

New Cayman Chemical Products - Sept 17th, 2013
New Cayman Chemical Products - Sept 17th, 2013New Cayman Chemical Products - Sept 17th, 2013
New Cayman Chemical Products - Sept 17th, 2013Cayman Chemical
 
Macrocycles As Bace 1 Inhibitors
Macrocycles As Bace 1 InhibitorsMacrocycles As Bace 1 Inhibitors
Macrocycles As Bace 1 InhibitorsYifang Huang
 
BioMAP<sup>®</sup> Primary Human Cell-Based Systems for Drug Discovery
BioMAP<sup>®</sup> Primary Human Cell-Based Systems for Drug DiscoveryBioMAP<sup>®</sup> Primary Human Cell-Based Systems for Drug Discovery
BioMAP<sup>®</sup> Primary Human Cell-Based Systems for Drug DiscoveryBioMAP® Systems
 
academic / small company collaborations for rare and neglected diseasesv2
 academic / small company collaborations for rare and neglected diseasesv2 academic / small company collaborations for rare and neglected diseasesv2
academic / small company collaborations for rare and neglected diseasesv2Sean Ekins
 
Juliane Carvalho Cancer Biology Presentation
Juliane Carvalho Cancer Biology PresentationJuliane Carvalho Cancer Biology Presentation
Juliane Carvalho Cancer Biology PresentationBrazilPharmaNews.com
 
Translational Genomics and Prostate Cancer: Meet the NGS Experts Series Part 2
Translational Genomics and Prostate Cancer: Meet the NGS Experts Series Part 2Translational Genomics and Prostate Cancer: Meet the NGS Experts Series Part 2
Translational Genomics and Prostate Cancer: Meet the NGS Experts Series Part 2QIAGEN
 
marine anticancer drugs'.pptx
marine anticancer drugs'.pptxmarine anticancer drugs'.pptx
marine anticancer drugs'.pptxTarkeshwar Dubey
 
ZP Summer 2015 Poster
ZP Summer 2015 PosterZP Summer 2015 Poster
ZP Summer 2015 PosterZaw Phyo
 
A novel platform for in situ, multiomic, hyper-plexed analyses of systems bio...
A novel platform for in situ, multiomic, hyper-plexed analyses of systems bio...A novel platform for in situ, multiomic, hyper-plexed analyses of systems bio...
A novel platform for in situ, multiomic, hyper-plexed analyses of systems bio...Rafael Casiano
 
Aditya - Cell Cycle Article Presentation.pptx
Aditya - Cell Cycle Article Presentation.pptxAditya - Cell Cycle Article Presentation.pptx
Aditya - Cell Cycle Article Presentation.pptxArPratiwiHasanuddin1
 
TTT Presentation Li Ching Sheng [Repaired]
TTT Presentation Li Ching Sheng [Repaired]TTT Presentation Li Ching Sheng [Repaired]
TTT Presentation Li Ching Sheng [Repaired]Li Ching Sheng
 
2016 RBC RETREAT POSTER TEMPLATE_SMP
2016 RBC RETREAT POSTER TEMPLATE_SMP2016 RBC RETREAT POSTER TEMPLATE_SMP
2016 RBC RETREAT POSTER TEMPLATE_SMPSagar M. Patel
 
Metabolic investigation of segmental overgrowth: new insights in pathogenic m...
Metabolic investigation of segmental overgrowth: new insights in pathogenic m...Metabolic investigation of segmental overgrowth: new insights in pathogenic m...
Metabolic investigation of segmental overgrowth: new insights in pathogenic m...BiologInc
 
In Vitro Metabolic, CYP and Transporter Characterization of PTI-125, a Novel ...
In Vitro Metabolic, CYP and Transporter Characterization of PTI-125, a Novel ...In Vitro Metabolic, CYP and Transporter Characterization of PTI-125, a Novel ...
In Vitro Metabolic, CYP and Transporter Characterization of PTI-125, a Novel ...Covance
 
Yuliya I. Petrova, Barry M. Gumbiner. Role of E-cadherin cell surface activat...
Yuliya I. Petrova, Barry M. Gumbiner. Role of E-cadherin cell surface activat...Yuliya I. Petrova, Barry M. Gumbiner. Role of E-cadherin cell surface activat...
Yuliya I. Petrova, Barry M. Gumbiner. Role of E-cadherin cell surface activat...Yuliya I. Petrova, PhD
 
Radiation Protection : Phospholipase A
Radiation Protection : Phospholipase ARadiation Protection : Phospholipase A
Radiation Protection : Phospholipase ADmitri Popov
 

Semelhante a UMich meeting seminar on 03-12-2014 v1.pptx [Autosaved] (20)

New Cayman Chemical Products - Sept 17th, 2013
New Cayman Chemical Products - Sept 17th, 2013New Cayman Chemical Products - Sept 17th, 2013
New Cayman Chemical Products - Sept 17th, 2013
 
Macrocycles As Bace 1 Inhibitors
Macrocycles As Bace 1 InhibitorsMacrocycles As Bace 1 Inhibitors
Macrocycles As Bace 1 Inhibitors
 
BioMAP<sup>®</sup> Primary Human Cell-Based Systems for Drug Discovery
BioMAP<sup>®</sup> Primary Human Cell-Based Systems for Drug DiscoveryBioMAP<sup>®</sup> Primary Human Cell-Based Systems for Drug Discovery
BioMAP<sup>®</sup> Primary Human Cell-Based Systems for Drug Discovery
 
academic / small company collaborations for rare and neglected diseasesv2
 academic / small company collaborations for rare and neglected diseasesv2 academic / small company collaborations for rare and neglected diseasesv2
academic / small company collaborations for rare and neglected diseasesv2
 
Juliane Carvalho Cancer Biology Presentation
Juliane Carvalho Cancer Biology PresentationJuliane Carvalho Cancer Biology Presentation
Juliane Carvalho Cancer Biology Presentation
 
linked in PRESENTATION
linked in PRESENTATIONlinked in PRESENTATION
linked in PRESENTATION
 
Translational Genomics and Prostate Cancer: Meet the NGS Experts Series Part 2
Translational Genomics and Prostate Cancer: Meet the NGS Experts Series Part 2Translational Genomics and Prostate Cancer: Meet the NGS Experts Series Part 2
Translational Genomics and Prostate Cancer: Meet the NGS Experts Series Part 2
 
IACR 2016 poster
IACR 2016 posterIACR 2016 poster
IACR 2016 poster
 
marine anticancer drugs'.pptx
marine anticancer drugs'.pptxmarine anticancer drugs'.pptx
marine anticancer drugs'.pptx
 
ZP Summer 2015 Poster
ZP Summer 2015 PosterZP Summer 2015 Poster
ZP Summer 2015 Poster
 
fonc-06-00181
fonc-06-00181fonc-06-00181
fonc-06-00181
 
A novel platform for in situ, multiomic, hyper-plexed analyses of systems bio...
A novel platform for in situ, multiomic, hyper-plexed analyses of systems bio...A novel platform for in situ, multiomic, hyper-plexed analyses of systems bio...
A novel platform for in situ, multiomic, hyper-plexed analyses of systems bio...
 
Aditya - Cell Cycle Article Presentation.pptx
Aditya - Cell Cycle Article Presentation.pptxAditya - Cell Cycle Article Presentation.pptx
Aditya - Cell Cycle Article Presentation.pptx
 
TTT Presentation Li Ching Sheng [Repaired]
TTT Presentation Li Ching Sheng [Repaired]TTT Presentation Li Ching Sheng [Repaired]
TTT Presentation Li Ching Sheng [Repaired]
 
2016 RBC RETREAT POSTER TEMPLATE_SMP
2016 RBC RETREAT POSTER TEMPLATE_SMP2016 RBC RETREAT POSTER TEMPLATE_SMP
2016 RBC RETREAT POSTER TEMPLATE_SMP
 
Metabolic investigation of segmental overgrowth: new insights in pathogenic m...
Metabolic investigation of segmental overgrowth: new insights in pathogenic m...Metabolic investigation of segmental overgrowth: new insights in pathogenic m...
Metabolic investigation of segmental overgrowth: new insights in pathogenic m...
 
In Vitro Metabolic, CYP and Transporter Characterization of PTI-125, a Novel ...
In Vitro Metabolic, CYP and Transporter Characterization of PTI-125, a Novel ...In Vitro Metabolic, CYP and Transporter Characterization of PTI-125, a Novel ...
In Vitro Metabolic, CYP and Transporter Characterization of PTI-125, a Novel ...
 
Yuliya I. Petrova, Barry M. Gumbiner. Role of E-cadherin cell surface activat...
Yuliya I. Petrova, Barry M. Gumbiner. Role of E-cadherin cell surface activat...Yuliya I. Petrova, Barry M. Gumbiner. Role of E-cadherin cell surface activat...
Yuliya I. Petrova, Barry M. Gumbiner. Role of E-cadherin cell surface activat...
 
Petrova_Poster_12 09 2014_mod
Petrova_Poster_12 09 2014_modPetrova_Poster_12 09 2014_mod
Petrova_Poster_12 09 2014_mod
 
Radiation Protection : Phospholipase A
Radiation Protection : Phospholipase ARadiation Protection : Phospholipase A
Radiation Protection : Phospholipase A
 

UMich meeting seminar on 03-12-2014 v1.pptx [Autosaved]

  • 1. (-)-Epicatechin Selectively Radiosensitizes Cancer Cells and Stimulates Mitochondrial Activity in Cancer Cells by Inhibiting MAPK Pathway Hosam A. Elbaz, Ph.D. March 12th, 2014 Department of Radiation Oncology, Center for Molecular Medicine and Genetics, Wayne State University Detroit, MI 48201.
  • 2. Overview • Introduction • What is (-)-Epicatechin? • Experimental methods • (-)-Epicatechin and Mitochondrial Respiration • (-)-Epicatechin and Radiosensitization • Potential Mechanisms • Conclusion and Future Directions
  • 3. Introduction • Radiotherapy is ideal for most solid tumors. • Radiation resistance and adverse effects are frequently encountered. • Radiosensitizing agents would improve therapeutic outcome. • Most cancer types exhibit 40-60% reduction in mitochondrial activity and rely on aerobic glycolysis for energy (Warburg effect). • Drugs that increase mitochondrial respiration would interfere with the Warburg effect and could sensitize cancer cells to conventional therapy.
  • 4. What is (-)-Epicatechin? • A natural polyphenolic flavanol – Flavonoid family – Natural ingredient in cacao, green tea and dark chocolate – Antioxidant properties • Molecular Weight: 290.268097 Da • IUPAC name: (2R,3R)-2-(3,4-dihydroxyphenyl)-3,4-dihydro-2H-chromene-3,5,7-triol • It has a number of beneficial health effects.
  • 5. (-)-Epicatechin stimulated mitochondrial respiration and ETC protein expression Hüttemann H et al. FASEB J. 2012; vol. 26 no. 4 1413-1422
  • 6. Short term treatment of 40 µM (-)-Epicatechin enhances cytochrome c oxidase activity p < 0.05; * and ** compared to control 0 20 40 60 80 100 120 140 160 180 0 5 10 15 20 25 30 35 CcOSpecificActivity [O2nmol/min/mgoftotalprotein] Cytc [µM] Control 5 min 20 min ** *
  • 7. General hypothesis ↑ COX activity ↑ Mitochondrial respiration in cancer cells ↓ The Warburg metabolism and ↑ ROS production in cancer cells ↑ Cellular stress ↑ Sensitivity to cell death (-)-Epicatechin
  • 8. Experimental methods • Cytochrome c oxidase activity • Cell lines: • Panc-1 • MIA PaCa-2 • U87 • Normal human dermal fibroblasts (NHDF) • Clonogenic survival assay • Enzymes for checkpoint and OXPHOS complexes • P-Chk2: phosphorylated checkpoint kinase protein 2 at Thr68 • p21. • P-Erk2: phosphorylated extracellular kinase 2 • OXPHOS complexes: • Complex I: NDUFB6 subunit • Complex II: 70kDa subunit • Complex III: Core 1 subunit • Complex IV: subunit 1 • Complex V: α subunit
  • 9. (-)-Epicatechin increases mitochondrial activity in Panc-1 cells but not in normal human dermal fibroblast (NHDF) cells COX activity for Panc-1 Cells (-)-Epicatechin (M) O2consumption (nmol/min/mgprotein) 0 20 50 100 200 0 10 20 30 * * * COX activity for NHDF Cells (-)-Epicatechin (M) O2consumption (nmol/min/mgprotein) 0 100 0 5 10 15 A B
  • 10. (-)-Epicatechin sensitizes cancer cell lines to irradiation Panc-1 IR dose (Gy) Survivalfraction 0 2 4 6 8 0.01 0.1 1 Control (-)-Epicatechin (20 M) U87 IR dose (Gy) Survivalfraction 0 2 4 6 8 0.01 0.1 1 Control (-)-Epicatechin (20 M) MIA PaCa-2 IR dose (Gy) Survivalfraction 0 2 4 6 8 0.01 0.1 1 Control (-)-Epicatechin (20 M) A B C D E(-)-Epicatechin alone (-)-Epicatechin (M) Survivalfraction 0 25 50 100 200 0.0 0.2 0.4 0.6 0.8 * * (-)-Epicatechin + 6 Gy (-)-Epicatechin (M) Survivalfraction 0 25 50 100 200 0.00 0.02 0.04 0.06 0.08 * * *
  • 11. (-)-Epicatechin does not sensitize NHDF cells to radiation. NHDF Cells IR dose (Gy) Survivalfraction 0 2 4 6 8 0.01 0.1 1 Control (-)-Epicatechin (20 M) A B C NHDF Survival with EC and 6Gy (-)-Epicatechin (M) Survivalfraction 0 100 0.000 0.001 0.002 0.003 * NHDF Survival with EC alone (-)-Epicatechin (M) Survivalfraction 0 20 0.00 0.02 0.04 0.06 0.08
  • 12. (-)-Epicatechin and irradiation modestly manipulate ETC protein expression RelativeexpressionC om 1-N D U FP6C om 2-70kD aC om 3-core 1 C O X-1 1 C om 5- 0.0 0.5 1.0 1.5 2.0 0 M / 0 Gy 20 M / 0 Gy 100 M / 0 Gy 200 M / 0 Gy Relativeexpression C om 1-N D U FP6C om 2-70kD aC om 3-core 1 C O X-1 1 C om 5- 0.0 0.5 1.0 1.5 2.0 0 M / 6 Gy 20 M / 6 Gy 100 M / 6 Gy 200 M / 6 Gy** B C
  • 13. Hypothesis: Activating cytochrome c oxidase increases mitochondrial membrane potential m and free radical production. O2 •–generation [nmol/mg/min] H2O2generation [nmol/mg/min] [Reviewed in Liu, S. (1999) J Bioenerg Biomembr 31:367-76] [Reviewed in Bin-Bing S. Zhou & Jiri Bartek. (2004) Nature Reviews Cancer 4, 216-225]
  • 14. (-)-Epicatechin and irradiation stimulate Chk2 phosphorylation (Thr68) and p21 expression in Panc-1 Cells. p21 in 6 Gy Exposed Cells (-)-Epicatechin (M)Relativeexpression 0 20 0.0 0.5 1.0 1.5 2.0 * A B 0 Gy 6 Gy - + - + IR (-)-Epicatechin 20 µM p21 GAPDH 0 Gy 6 Gy - + - + IR (-)-Epicatechin 20 µM P-Chk2 Chk2 GAPDH P-Chk2 in 6 Gy Exposed Cells (-)-Epicatechin (M) Relativeexpression 0 20 0.0 0.5 1.0 1.5 2.0 *
  • 15. (-)-Epicatechin and irradiation do not stimulate Chk2 phosphorylation or p21 expression in NHDF cells A B
  • 16. (-)-Epicatechin stimulates caspase 3 cleavage in Panc-1 cells. Pro-caspase 3 Cleaved caspase 3 β-actin - + - +(-)-Epicatechin IR 0 Gy 6 Gy
  • 17. EGFR signalling inhibits mitochondrial function. Demory M L et al. J. Biol. Chem. 2009;284:36592-36604 Modified from Hüttemann H et al. Adv. Exp. Med. Biol. 2012;748:237-64 Receptor tyrosine kinase signaling ↑ EGFR translocation to the mitochondria COX activity ↓ Warburg metabolism ↑ ∞ Cell proliferation MAPK members interact with COX (-)-Epicatechin
  • 18. (-)-Epicatechin and radiation inhibit Erk phosphorylation in Panc-1 cells A P-Erk1/2 Erk1/2 (-)-Epicatechin (µM) 0 20 50 100 200 GAPDH B 6Gy + (-)-Epicatechin (µM) 0 20 50 P- Erk1/2 Erk1/2 GAPDH Erk2 phosphorylation in Panc-1 cells (-)-Epicatechin (M) Relativeexpression 0 20 50 100 200 0.00 0.25 0.50 0.75 1.00 1.25 * * * P-Erkin6GyExposedPanc-1Cells (-)-Epicatechin(M) Relativeexpression 0 20 50 0.0 0.2 0.4 0.6 0.8 1.0 *
  • 19. EGF reverses (-)-epicatechin’s stimulation of mitochondrial respiration in Panc-1 cells O2consumption (nmol/min/mgprotein) Control EC EGF EC+EGF 0 5 10 15 20 25 * *
  • 20. EGF reverses (-)-epicatechin’s inhibition of Panc-1 clonogenic survival Survivalfraction Control EC EGF EC+EGF 0.0 0.5 1.0 1.5 2.0 2.5 * * *
  • 21. Discussion and Conclusion • (-)-Epicatechin – Increases COX activity and potentially reverses Warburg effect. – “selectively” sensitizes cancer cells to irradiation. • (-)-Epicatechin and radiation – increased P-Chk2 and p21 levels in Panc-1 cells – No effect in NHDF cells. • (-)-Epicatechin with or without radiation. – reduced Erk phosphorylation • (-)-Epicatechin reduced EGF’s effect mitochondrial activity and Panc-1 clonogenesis. (-)-Epicatechin ↑ COX activity ↑ Mitochondrial respiration in cancer cells ↓ Warburg metabolism ↓Cell proliferation ↑ Cellular stress ↓ MAPK signaling ↑ Sensitivity to cell death
  • 22. Future Directions • How does (-)-epicatechin regulate mitochondrial respiration via MAPK signaling in cancer cells? • Is (-)-epicatechin’s radiosensitization mediated by reduced MAPK signaling? • How does (-)-epicatechin’s effect on MAPK signaling cause radiosensitization in cancer cells? • Can (-)-epicatechin be used as a radiosensitizer in vivo? • Animal model examination • Efficacy vs. safety • Can (-)-epicatechin sensitize cancer cells to chemotherapy?
  • 23. Acknowledgements • Principle investigators – Steven Zielske – Maik Hüttemann • Angelika Burger Shared Postdoctoral Award, Karmanos Cancer Institute • Department of Radiation Oncology • Center for Molecular Medicine and Genetics • WSU Office for Vice President for Research • Zielske lab – Current members • Morgan Laney – Former members • Ethan Brock • Aisha Fasih • Deborah Antwih • Kristina Gabbarah • Hüttemann lab – Icksoo Lee – Jenney Liu – Joseph Shay – Gargi Mahapatra